Solid Tumor Oncology

Anatomic Pathology

Morphology

Surgical Pathology Consultation [SPC]

Immunohistochemistry & Special Stains

Refer to A-Z listing for IHC Markers

Cytogenetics

Chromosome Analysis Solid Tumor [CYTO ST]

Molecular Oncology

Next Generation Sequencing (NGS)

BRAF Mutation Analysis [M BRAF]

Colorectal Cancer NGS Panel [M COLON NGS]
BRAF, KRAS, NRAS

EGFR Mutation Analysis [M EGFR]

GIST NGS Panel - *KIT, PDGFRA, BRAF* [M GIST]

IDH1/IDH2 Mutation Analysis [M IDH1/2]

KRAS Mutation Analysis [M KRAS]

Lung Cancer NGS Panel [M LUNG NGS]
BRAF, EGFR, KRAS, NRAS

Melanoma Cancer NGS Panel [M MELAN NGS]
BRAF, KIT, NRAS

Solid Tumor 8 Gene NGS Panel [M 8GENE NGS]
BRAF, EGFR, IDH1, IDH2, KIT, KRAS, NRAS, PDGFRA

Fluorescence in situ Hybridization

ALK 2p23 rearrangement [FP ALK]

BCL6 3q27 rearrangement [FP BCL6]

Burkitt / "Double Hit" Large B-cell Lymphoma Panel [FP BURKITT]
C-MYC, BCL2, BCL6

C-MYC 8q24 rearrangement [FP CMYC]

EGFR amplification 7p11.2 [FP EGFR]

Glioma Panel [1p-,19q-; *EGFR* amp] [FP GLIO MAP]

HER2/neu Breast Cancer [FP HER2]

HER2/neu Gastric Cancer [FP HER2 GA]

IGH 14q32 rearrangement [FP IGH]

IGH/BCL1 (CCND1) t(11;14) [FP BCL1]

IGH/BCL2 t(14;18) [FP BCL2]

*IGH/MALT*1 t(14;18) [FP IGH MALT]

IGH/MYC t(8;14) [FP IGH MYC]

MALT1 18q21 rearrangement [FP MALT]

Oligodendroglioma, 1p-;19q- [FP GLI]

ROS1 6q22.1 rearrangement [FP ROS1]

Hematology Oncology

Anatomic Pathology

Morphology

Bone Marrow Pathology Evaluation [BMPE]

Surgical Pathology Consultation [SPC]

Immunohistochemistry & Special Stains

Refer to A-Z listing for IHC Markers

Cytogenetics

Chromosome Analysis Bone Marrow [CYTO BM]

Chromosome Analysis Lymphoma (Lymph Node) [CYTO LN]

Chromosome Analysis Leukemic Peripheral Blood [CYTO LPB]

Flow Cytometry

Flow Cytometry Leukemia / Myeloma / Lymphoma [FLOW]

Flow Cytometry Technical Only [FLOW TC]

Flow Cytometry and Morphology [FLOW M]

Bronchoalveolar Lavage [FLOW BAL]
CD3, CD4, CD8, CD16, CD45, CD4:CD8 ratio

Leukocyte Adhesion Deficiency -CD11a, CD11b, CD11c, CD18 [FLOW LAD]

Paroxymal Nocturnal Hemoglobinuria - High Sensitivity
FLAER, CD14, CD24, CD59 [FLOW PNH]

ZAP-70 [FLOW ZAP 70]

Molecular Oncology

Next Generation Sequencing (NGS)

Calreticulin type 1 / type 2 Mutation Analysis [M CALR]

IgVH Somatic Hypermutation [M IgVH]

JAK2 Exon 12 Mutation [M JAK2 EX12]

MPL Exon 10 Mutation [M MPL]

MYD88 p.L265P Mutation [M MYD88]

Myeloid Neoplasms Extended Mutation Panel [M MPN Extended]
JAK2 (V617F and Exon 12), CALR (Type 1 and 2), MPL, ASXL1, CBL, CSF3R, ETV6/TEL, EZH2, IDH1, IDH2, KIT, KRAS, NRAS, RUNX1, SETB1, SF3B1, SRSF2, TET2, TP53

Myeloproliferative Neoplasms Core Mutation Panel [M MPN Core]
JAK2 V617F, JAK2 EXON 12, CALR, MPL

Polymerase Chain Reaction (PCR)

ABL Kinase Gene Mutation; Gleevec® Resistance [M ABL G]

AML Mutation Analysis - *FLT3, NPM1* [M AML]

B-cell Immunoglobulin Heavy Chain Gene Rearrangement [M BCELL]

B-cell Immunoglobulin Kappa Light Chain Rearrangement [M IGK]

BCL2 t(14;18) Gene Rearrangement [M BCL2]

BCR/ABL qRT PCR Major p210 & Minor p190 transcripts[M BCR ABL]

CEBPA Mutation [M CEBPA]

FLT3 Mutation [M FLT3]

JAK2 V617F Mutation [M JAK2]

KIT Mutations in AML [M KIT AML]

KIT D816V Mutation [M KIT P]

NPM1 Mutation [M NPM1]

PML RARA Short and Long form by qRT PCR [M PML RARA]

T-Cell Receptor Gamma Gene Rearrangement [M TCR]

Rev 22JUN2017

Fluorescence in situ Hybridization (FISH)

Hematology Panels

Adult Acute Lymphoblastic Leukemia Panel [F AALL]
[t(9;22), t(12;21), *MLL*(KMT2A)]

Burkitt / "Double Hit" Large B-cell Lymphoma Panel [F BURKITT]
[*C-MYC, BCL2, BCL6*]

Chronic Lymphocytic Leukemia Panel [F CLL]
[*MYB* (6q23), *ATM* (11q22.3), +12, *DLEU1* (13q14.3), *TP53* (17p13)]

Myelodysplasia Panel [F MDS] [-5/5q-, -7/7q-, +8, 20q-]

Myeloproliferative Neoplasms Panel [F MPD]
[+8, t(9;22), 13q-, 20q-]

Plasma Cell Neoplasm Panel [F MM]
[1p-, 1q+, +5, +9, t(11;14), 13q-, +15, 17p-]
reflex t(4;14) / t(14;16)

Hematology Probes

AML1(*RUNX1*)/*ETO*(RUNXT1) t(8;21) [F AML ETO]

API2/MALT1 t(11;18) [F API MALT]

ATM/CEP11 deletion 11q22.3 [F ATM]

BCL6 3q27 rearrangement [F BCL6]

BCR/ABL1 t(9;22) [F BCR ABL]

CBFB t(16;16), inv(16) [F CBFB]

CEP 7 -7/7q31 [F CEP7]

C-MYC 8q24 rearrangement [F CMYC]

Deletion 7q22 [D7S796, D7S658]/7q31.2 [D7S486] [F 7q]

Deletion 13q14.3 [F D1314]

Deletion 20q12 [F D20]

EGR1 5q deletion, monosomy 5 [F EGR1]

FIPIL1/PDGFRA 4q12 gene rearrangement [F 4q12]

IGH 14q32 rearrangement [F IGH]

IGH/BCL1 (*CCND1*) t(11;14) [F BCL1]

IGH/BCL2 t(14;18) [F BCL2]

IGH/FGFR3 t(4;14) [F FGFR3]

IGH/MAF t(14;16) [F IGH MAF]

IGH/MALT1 t(14;18) [F IGH MALT]

IGH/MYC t(8;14) [F IGH MYC]

MALT1 18q21 rearrangement [F MALT]

MLL (KMT2A) 11q23 Gene Rearrangement [F MLL]

MYB 6q deletion [F MYB]

PDGFRB Gene Rearrangement [F PDGFRB]

PML/RARA t(15,17) [F PML RARA]

TEL(*ETV6*)/*AML1*(*RUNX1*) t(12;21) [F TEL AML1]

TP53 17p13 deletion [F P53]

Trisomy 5, 9, 15 [F T5T9T15]

Trisomy 8 [F T8]

Women's Health

Medical Genetics

Cystic Fibrosis Luminex x-TAG 39 Variant Assay [M CF 39]

Cystic Fibrosis MiSeqDx 139 Variant-Assay by NGS [M CF NGS 139]

Cystic Fibrosis MiSeqDx Clinical Sequence Assay by NGS
[M CF NGS SEQ]

STD and Infectious Disease

Chlamydia Trachomatis, Qualitative by Aptima COMBO® 2 TMA [CT]

Human Papillomavirus Genotyping [HPV G]

Human Papillomavirus High Risk by Aptima HPV [HPV HR]

Herpes Simplex Virus Type 1 and 2 Qualitative by PCR [HSV]

Neisseria Gonorrhoeae Qualitative by Aptima COMBO® 2 TMA [NG]

Trichomonas Vaginalis by Aptima [TV]

Other

Fluorescence in situ Hybridization (FISH)

Bladder Cancer Panel [+3,+7,+17,9p21-] [F URO]

Molar Pregnancy Panel [+13,+18,+21, X, Y] [FP ANEU]

Cytogenetics

Chromosome Analysis Peripheral Blood (Constitutional) [CYTO PB]

Chromosome Analysis Products of Conception [CYTO POC]

(Refer to web site for tests performed at affiliate lab)